Evidence map›Paper›PMID 29131323›Full record

ArticleCancer2018

Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy.

Timothy P Pearman, Jennifer L Beaumont, Daniel Mroczek, Mary O'Connor, David Cella

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05053607 (Clinical and Patient Reported Outcomes for Individuals with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab), which is not on this map. Cited by 62 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 3 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05053607 narecruitingnot on this mapstarted 2022, after this paper: background citation

Clinical and Patient Reported Outcomes for Individuals with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab: Real-World Insights from Patient Reported, Wearable, and Qualitative Data in the Context of Digital Health Coaching

TypeinterventionalSponsorPack HealthRan2022 to 2025Enrolled50ConditionsMultiple Myeloma, Refractory Multiple MyelomaArmsDigital Health Coaching Program, Fitbit
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology/NSABP R04.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Trial
  11. The FACT-GP5 as a global tolerability measure: responsiveness and robustness to missing assessments.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: AtezolizumabClinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Trial
  20. Trial

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Timothy P PearmanDepartment of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0003-2459-8986
Jennifer L BeaumontDepartment of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Daniel MroczekDepartment of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Mary O'ConnorDepartment of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
David CellaDepartment of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Northwestern University · US

Funding

PERSONALITY AND WELL BEING TRAJECTORIES IN ADULTHOODR01AG018436 · NIA · PURDUE UNIVERSITY WEST LAFAYETTE · PI MROCZEK, DANIEL K. · 2000 to 2020
$6.7M
NIA NIH HHS R01 AG018436
6 · The paper itself

Abstract

backgroundThe improving efficacy of cancer treatment has resulted in an increasing array of treatment-related symptoms and associated burdens imposed on individuals undergoing aggressive treatment of their disease. Often, clinical trials compare therapies that have different types, and severities, of adverse effects. Whether rated by clinicians or patients themselves, it can be difficult to know which side effect profile is more disruptive or bothersome to patients. A simple summary index of bother can help to adjudicate the variability in adverse effects across treatments being compared with each other.

methodsAcross 4 studies, a total of 5765 patients enrolled in cooperative group studies and industry-sponsored clinical trials were the subjects of the current study. Patients were diagnosed with a range of primary cancer sites, including bladder, brain, breast, colon/rectum, head/neck, hepatobiliary, kidney, lung, ovary, pancreas, and prostate as well as leukemia and lymphoma. All patients were administered the Functional Assessment of Cancer Therapy-General version (FACT-G). The single item "I am bothered by side effects of treatment" (GP5), rated on a 5-point Likert scale, is part of the FACT-G. To determine its validity as a useful summary measure from the patient perspective, it was correlated with individual and aggregated clinician-rated adverse events and patient reports of their general ability to enjoy life.

resultsAnalyses of pharmaceutical trials demonstrated that mean GP5 scores ("I am bothered by side effects of treatment") significantly differed by maximum adverse event grade (P<.001) in all trials, with a clear trend toward increasing GP5 scores with level of increasing adverse event grade. Effect sizes ranged from 0.13 to 0.46. Analyses of cooperative group trials demonstrated a significant correlation between GP5 and item GF3 ("I am able to enjoy life") in the predicted direction.

conclusionsThe single FACT-G item "I am bothered by side effects of treatment" is significantly associated with clinician-reported adverse events and with patients' ability to enjoy their lives. It has promise as an overall summary measure of the burden of a given set of treatment toxicities compared with another. Future research can identify the contribution of individual side effects compared with one another in terms of how each may contribute to overall bother. Cancer 2018;124:991-7. © 2017 American Cancer Society.

Indexed as

Patient Reported Outcome MeasuresSurveys and QuestionnairesAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsFemaleHumansMaleMiddle AgedNeoplasmsQuality of LifeReproducibility of ResultsYoung AdultAntineoplastic Agentscancer treatmentclinical trialsmeasurement scienceoncology practiceoutcomespatient-reported outcomes (PROs)quality of life

Identifiers

PMID29131323
PMCPMC5892190
OpenAlexW2769746786

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.